Neurovalens recently announced that the U.S. FDA has approved the market launch of its non-invasive neuromodulation device for weight management, Modius Lean, marking the official entry of neuromodulation technology into the weight management market. Neuroscience research is shifting the battlefield of weight loss from the gastrointestinal tract and fat cells toward the body’s most sophisticated central processor—the brain, and weight management may be heading toward a paradigm revolution from “intervening in metabolism” to “reshaping the brain.”
From the Periphery to the Core: How Neuroscience Redefines Weight-Loss Treatment
Traditional weight-loss methods—whether suppressing appetite with drugs or surgically modifying the digestive system—mostly work by influencing “downstream” links such as energy intake or absorption. The latest neuroscience findings, however, suggest that one key “upstream” root cause of obesity lies in a shift of the brain’s “set point” for energy balance.
Specifically, the “central melanocortin system” in the arcuate nucleus of the hypothalamus functions like a thermostat: based on signals from throughout the body (such as hormones, nutrients, and neural inputs), it sets and strives to maintain a preset body weight or fat level. Environmental factors (such as high-calorie diets and stress) may permanently “turn up” this set point, causing the body to resist weight-loss efforts and triggering weight regain. The core goal of neuromodulation technology is precisely to directly intervene in the brain—especially the hypothalamus—to “reset” this erroneous fat set point.
Taking Modius Lean as an example, it uses electrical stimulation of the vestibular nerve, which is based on this very theory. The vestibular nerve is primarily responsible for balance, but research has found that long-term stimulation of this nerve, via a “vestibular–hypothalamic pathway,” may activate regions in the hypothalamus that regulate energy homeostasis. In biological terms, sustained vestibular input may be interpreted by the brain as a signal that the “body is frequently physically active,” thereby proactively mobilizing fat for energy and reducing fat storage levels.
A key randomized controlled trial published in Scientific Reports showed: when combined with a low-calorie diet, the active group using this device achieved an average reduction in visceral fat of 12.6%, significantly better than the control group’s 4.7%. This data is highly meaningful because, compared with subcutaneous fat, visceral fat is the “culprit” behind metabolic complications such as diabetes and cardiovascular disease. This indicates that neuromodulation may open up a new, precision weight-loss pathway centered on improving metabolic health.
Panorama of Existing Therapies: Iteration From Traditional Suppression to Precise Targeting
Compared with traditional mainstream therapies, neuromodulation, as an emerging approach, has clear strengths and weaknesses and a uniquely defined positioning.
| Neuromodulation Devices | GLP-1 Receptor Agonists | Metabolic Bariatric Surgery | |
| Mechanism of action | Regulates the brain, resets the fat set point | Mimics gut hormones, suppresses appetite | Restricts stomach capacity or alters digestive pathways |
| Core advantages | – Non-invasive, high safetyTargets harmful visceral fat – No systemic drug side effects | Significant weight-loss effectProven cardiovascular benefits | – Most durable, most potent effect – Can significantly alleviate multiple obesity complications |
| Major limitations | – Overall weight-loss magnitude is relatively moderate – Requires long-term, consistent useMust be combined with lifestyle interventions | – Requires long-term injections – Common gastrointestinal side effects – Weight regain is common after discontinuation | – Invasive surgery, with risks – Long recovery period – May lead to long-term malnutrition |
| Commercial positioning | Lifestyle-assisting device: suitable for people with mild-to-moderate obesity and high-risk populations | Prescription drug: suitable for patients with moderate-to-severe obesity and comorbid cardiovascular disease | Ultimate medical intervention: suitable for patients with morbid obesity for whom other methods are ineffective |
In addition, other non-invasive brain stimulation technologies have also shown potential. For example, rTMS and tDCS technologies acting on the dorsolateral prefrontal cortex have been proven to effectively reduce food craving and intake, providing new tools for controlling impulsive eating. This further enriches the application scenarios of neuromodulation at the level of behavior modification.
Innovation Frontier: Neuromodulation Weight-Loss Solutions Under Development Globally
Globally, beyond the already approved Modius Lean, multiple solutions based on different neural mechanisms demonstrate the technological diversity of this field:
a. Innovative devices and digital therapeutics:
- Brain neuroplasticity platform: The Swiss company Neuria has developed a “brain recalibration platform” based on smartphone video games, aiming to subtly change subconscious brain processes related to food cravings through gamified neurotraining. The company has partnered with insurers and plans to launch a B2B subscription service in Switzerland and the United States.
- Vagus nerve stimulation: The U.S. FDA previously approved EnteroMedics’ vBloc system for market launch. It produces satiety by implanting a device to intermittently block vagus nerve signals between the stomach and the brain. Although the weight-loss effect is relatively good, due to multiple reasons—high cost (tens of thousands of U.S. dollars), lack of insurance support, patients’ concerns about invasive therapy, and inconveniences brought by subsequent programming and battery replacement—the vBloc system did not achieve commercial success.
b. Innovative drugs
- New delivery pathway: A team at the National University of Singapore reported a highly imaginative study in the journal Cell: they engineered a probiotic that can target and colonize the olfactory epithelium in the nasal cavity, enabling it to continuously secrete hormones such as leptin and deliver them directly to the brain via the olfactory nerve, bypassing the blood–brain barrier. Animal experiments show that this method can effectively suppress appetite and reduce body weight.
- New target: In China, a novel peptide drug UBT37034, independently developed by The United Laboratories, achieves weight loss by selectively acting on the neuropeptide Y2 receptor in the brain. The drug has been approved for clinical trials in China and the United States, and its potential for combination use with GLP-1 drugs is being explored.
The Vast Sea of Stars: Market Status and Development Trends of Neuromodulation
Neuromodulation technology was not born solely for weight loss. Its core market is currently still firmly rooted in the vast field of treatment for neurological and psychiatric diseases. The technology is already a mature or frontier solution for diseases such as chronic pain, Parkinson’s disease, epilepsy, and depression; its market foundation is deep and is expanding with strong momentum. The core market of neuromodulation is rapidly expanding from traditional neuropsychiatric disease treatment to new areas such as metabolic health.
a. Global market: The global neuromodulation device market is expanding at a compound annual growth rate of about 9%, and its scale is expected to exceed USD 11.0 billion by 2027. The technology shows clear trends of miniaturization, intelligence, and integration with digital therapeutics.
b. China market: China is one of the fastest-growing markets in the neuromodulation field. The market size in 2025 is estimated at RMB 4.0–5.0 billion (approx. USD 0.56–0.69 billion), and it has continued to grow at a high double-digit percentage rate in recent years. The growth rate is significantly higher than the global average, reflecting huge clinical demand and market potential.
c. Potential blue ocean: For the relatively mature neuromodulation industry, entering the global weight management market at the “hundreds of billions of U.S. dollars” level will not simply mean adding one more indication; it may bring the following structural impacts:
- Opening a second curve of exponential growth: The enormous patient base of obesity far exceeds the total number of patients with existing neurological and psychiatric diseases. A successful weight-loss indication can transform neuromodulation devices from specialized therapeutic tools into mass-market health management consumer products, substantially raising the market ceiling.
- Reshaping the industrial chain and business model: Non-invasive technologies greatly lower the treatment and technical threshold of neuromodulation, and are expected to expand from hospital neurosurgery/pain departments to endocrinology, weight-loss clinics, high-end health management institutions, and even directly to consumers’ e-commerce platforms. The business model may also shift from one-time device sales to a combination of “device + ongoing service subscription.”
Conclusion
With neuromodulation technology entering the field of weight management, a new era of “brain-centered” health management is beginning. Technologically, it is no longer satisfied with short-term suppression of symptoms, but is instead committed to long-term neural correction of the root causes of metabolic imbalance. From a commercial perspective, the market logic may undergo profound change: the focus of corporate competition will shift from the performance of a single device to the capability to build comprehensive solutions of “precise neural intervention + personalized behavioral management + a digital service ecosystem.”
[Disclaimer]: The above content reflects analysis of publicly available information, expert insights, and BCC research. It does not constitute investment advice. BCC is not responsible for any losses resulting from reliance on the views expressed herein. Investors should exercise caution.